Bridging to transplant: allogeneic heart transplantation after xenografting.
Xenografting seems to be a solution to use to bridge time intervals when desperately needed allograft cannot be obtained. A following allograft was never ventured. Nine dogs (weight, 20 to 25 kg; age, 2 years) underwent right cervical heart transplantation. Donors were silver foxes (3 to 4 kg). The animals were treated by triple-drug therapy consisting of cyclosporine, methylprednisolone, and azathioprine in clinical dosages. For control, six recipients received only allogeneic hearts and the identical immunosuppression. After rejection of the xenograft, a second allogeneic heart was anastomosed subsequently to the same right cervical vessels. Routine histologic and immunohistologic examinations were performed. Thromboxane B2 and 6-keto-prostaglandin F1 alpha were determined daily in peripheral blood. After final rejection the sensitization of the recipient was controlled by hemagglutination test. Survival time of the xenografts was 9.6 +/- 1.2 days; the subsequent allogeneic hearts under the same therapy beat for 4.5 +/- 5.0 days. The average survival time of control hearts was 18 +/- 1.9 days. The five hyperacute second allografts showed signs of humoral rejection by absence of inflammation. The release of thromboxane B2 was different in hyperacute, accelerated, or cellular rejection. In contrast to the long-functioning grafts, thromboxane B2 persisted during hyperacute rejection at a high level. However, 6-keto-prostaglandin F1 alpha showed no significant differences between longtime survivors and hyperacute rejecting hearts. After xenogeneic transplantation, all recipients showed hemagglutinating titers between 1:4 and 1:16. Allogeneic grafts have a different kinetics of rejection after xenogeneic heart transplantation compared with control hearts. Thromboxane B2 seems to be an important mediator in hyperacute rejection.(ABSTRACT TRUNCATED AT 250 WORDS)
Hammer
C
C
Institute for Surgical Research, Ludwig-Maximilians-University, Klinikum Grosshadern, Munich, Germany.
Schütz
A
A
Pratschke
J
J
Breuer
M
M
Engelhardt
M
M
Brandl
U
U
Saumweber
D
D
Babic
R
R
Kemkes
B M
BM
Reichart
B
B
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000818:Animals; D001379:Azathioprine / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D004285:Dogs; D005589:Foxes; D006084:Graft Rejection / Q000276:immunology*; D006085:Graft Survival; D016027:Heart Transplantation / Q000276:immunology / Q000379:methods*; D006386:Hemagglutination Tests; D007165:Immunosuppression Therapy; D008775:Methylprednisolone / Q000627:therapeutic use; D013929:Thromboxane B2 / Q000097:blood; D013997:Time Factors; D014183:Transplantation, Heterologous / Q000276:immunology*; D014184:Transplantation, Homologous
D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D016572:Cyclosporine; D001379:Azathioprine; D008775:Methylprednisolone